2653201-38-6
Chemical Structure
(Rac)-Opnurasib
Synonym(s): (Rac)-JDQ-443;(Rac)-NVP-JDQ443
- CAS No.: 2653201-38-6
- Formula:C29H28ClN7O
- Molecular Weight:526.03
IUPAC Name: 1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one
InChIKey: AZUYLZMQTIKGSC-UHFFFAOYSA-N
SMILES: O=C(N1CC2(CC(C2)N3N=C(C(C4=C5C=NNC5=CC(C)=C4Cl)=C3C)C6=CC=C7C(C=NN7C)=C6)C1)C=C
Biological Activity: (Rac)-Opnurasib ((Rac)-JDQ-443; (Rac)-NVP-JDQ443) is the levorotomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(Rac)-Opnurasib | (Rac)-Opnurasib ((Rac)-JDQ-443; (Rac)-NVP-JDQ443) is the levorotomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. LIU BO, et al. PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS. Patent WO2021120890A1.
- [2]. Weiss A, Lorthiois E, Barys L, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022;candisc.0158.2022. [Content Brief]
Keywords
